Towards individualised treatment in childhood leukaemia

The Lancet Oncology

Volumn 11, Issue 6, 2010, Pages 502-503

  Veerman, Anjo JP ^a   Kaspers, Gertjan J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; GEMTUZUMAB OZOGAMICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW EXAMINATION; CANCER MORTALITY; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; DRUG TARGETING; EVENT FREE SURVIVAL; FLOW CYTOMETRY; HUMAN; MINIMAL RESIDUAL DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

EID: 77953531636     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70108-X     Document Type: Note

References (4)

1. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11:543-552.
2. Kaspers GJL, Zwaan CM Pediatric acute myeloid leukemia: towards high-quality cure of all patients. Haematologica 2007, 92:1519-1532.
3. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukaemia by multiparameter flowcytometry: the MRD-AML-BFM Study Group. J Clin Oncol 2006, 24:3686-3692.
4. Zwaan CM, Reinhardt C, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Brit J Haematol 2009, 148:768-776.